- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07392892
Et studie til at lære om undersøgelsesmedicinen PF-08634404 i kombination med kemoterapi ved gastroøsofageal cancer
EN FASE 2/3 INTERVENTIONEL UNDERSØGELSE AF PF-08634404 I KOMBINATION MED KEMOTERAPI BEHANDLINGSNAIVE DELTAGERE MED LOKALT FREMSKREDEN ELLER METASTATISK MAVE-, GASTROESOFAGEAL KRYDS ELLER SPISERØRSADENOKARCINOM
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studiesteder
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Ikke rekrutterer endnu
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
California
-
Atascadero, California, Forenede Stater, 93422
- Rekruttering
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, Forenede Stater, 91505
- Rekruttering
- UCLA Hematology/Oncology - Burbank
-
Encino, California, Forenede Stater, 91436
- Rekruttering
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, Forenede Stater, 90292
- Rekruttering
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, Forenede Stater, 91326
- Rekruttering
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, Forenede Stater, 94158
- Ikke rekrutterer endnu
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, Forenede Stater, 94158
- Ikke rekrutterer endnu
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, Forenede Stater, 93401
- Rekruttering
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, Forenede Stater, 93101
- Rekruttering
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, Forenede Stater, 90404
- Rekruttering
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80012
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, Forenede Stater, 80303
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, Forenede Stater, 80112
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, Forenede Stater, 80923
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Forenede Stater, 80218
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, Forenede Stater, 80220
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, Forenede Stater, 80113
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, Forenede Stater, 80228
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, Forenede Stater, 80120
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, Forenede Stater, 80124
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, Forenede Stater, 80504
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, Forenede Stater, 81003
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, Forenede Stater, 80260
- Rekruttering
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, Forenede Stater, 32117
- Ikke rekrutterer endnu
- Florida Cancer Specialists
-
Fleming Island, Florida, Forenede Stater, 32003
- Ikke rekrutterer endnu
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, Forenede Stater, 33410
- Ikke rekrutterer endnu
- Florida Cancer Specialists
-
Sebring, Florida, Forenede Stater, 33870
- Ikke rekrutterer endnu
- Florida Cancer Specialists
-
Wellington, Florida, Forenede Stater, 33414
- Ikke rekrutterer endnu
- Florida Cancer Specialists
-
West Palm Beach, Florida, Forenede Stater, 33401
- Ikke rekrutterer endnu
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, Forenede Stater, 60005
- Rekruttering
- Illinois Cancer Specialists
-
Bloomington, Illinois, Forenede Stater, 61704
- Rekruttering
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, Forenede Stater, 60631
- Rekruttering
- Illinois Cancer Specialists
-
Galesburg, Illinois, Forenede Stater, 61401
- Rekruttering
- Illinois CancerCare - Galesburg
-
Niles, Illinois, Forenede Stater, 60714
- Rekruttering
- Illinois Cancer Specialists
-
Ottawa, Illinois, Forenede Stater, 61350
- Rekruttering
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, Forenede Stater, 61554
- Rekruttering
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Forenede Stater, 61615
- Rekruttering
- Illinois CancerCare, P.C.
-
Peru, Illinois, Forenede Stater, 61354
- Rekruttering
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, Forenede Stater, 61571
- Rekruttering
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, Forenede Stater, 21401
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, Forenede Stater, 20817
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, Forenede Stater, 20613
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, Forenede Stater, 21044
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, Forenede Stater, 20876
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, Forenede Stater, 20774
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, Forenede Stater, 20850
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, Forenede Stater, 20904
- Rekruttering
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Rekruttering
- Renown Regional Medical Center
-
Reno, Nevada, Forenede Stater, 89502
- Rekruttering
- Renown Health Medical Oncology
-
Reno, Nevada, Forenede Stater, 89502
- Rekruttering
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, Forenede Stater, 07960
- Ikke rekrutterer endnu
- Atlantic Health System
-
Summit, New Jersey, Forenede Stater, 07901
- Ikke rekrutterer endnu
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, Forenede Stater, 11101
- Rekruttering
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, Forenede Stater, 11101
- Rekruttering
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, Forenede Stater, 10022
- Rekruttering
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45245
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Forenede Stater, 45242
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, Forenede Stater, 45211
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, Forenede Stater, 45014
- Rekruttering
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, Forenede Stater, 19020
- Rekruttering
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, Forenede Stater, 18901
- Rekruttering
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, Forenede Stater, 19044
- Rekruttering
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, Forenede Stater, 19047
- Rekruttering
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, Forenede Stater, 19063
- Rekruttering
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, Forenede Stater, 18960
- Rekruttering
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, Forenede Stater, 19096
- Rekruttering
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, Forenede Stater, 75063
- Rekruttering
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, Forenede Stater, 22201
- Rekruttering
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, Forenede Stater, 23320
- Rekruttering
- Virginia Oncology Associates
-
Fairfax, Virginia, Forenede Stater, 22031
- Rekruttering
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, Forenede Stater, 23666
- Rekruttering
- Virginia Oncology Associates
-
Manassas, Virginia, Forenede Stater, 20110
- Rekruttering
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, Forenede Stater, 23606
- Rekruttering
- Virginia Oncology Associates
-
Norfolk, Virginia, Forenede Stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
Reston, Virginia, Forenede Stater, 20190
- Rekruttering
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, Forenede Stater, 23456
- Rekruttering
- Virginia Oncology Associates
-
Woodbridge, Virginia, Forenede Stater, 22191
- Rekruttering
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- Rekruttering
- University of Washington Medical Center
-
Seattle, Washington, Forenede Stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Forenede Stater, 98104
- Rekruttering
- Harborview Medical Center
-
-
-
-
-
Paris, Frankrig, 75015
- Rekruttering
- Hôpital Européen Georges Pompidou
-
-
-
-
Central District
-
Petah Tikva, Central District, Israel, 4941492
- Rekruttering
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israel, 5265601
- Rekruttering
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, Israel, 6423906
- Rekruttering
- Sourasky Medical Center
-
-
-
-
-
Milan, Italien, 20141
- Rekruttering
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Rekruttering
- Aichi Cancer Center
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510655
- Rekruttering
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, Kina, 430079
- Rekruttering
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200031
- Rekruttering
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- Sichuan Cancer hospital
-
-
-
-
-
Bayamón, Puerto Rico, 00959
- Rekruttering
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, Puerto Rico, 00674
- Rekruttering
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spanien, 08035
- Rekruttering
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], Spanien, 32005
- Ikke rekrutterer endnu
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
-
Tainan, Taiwan, 704302
- Rekruttering
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 10002
- Rekruttering
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Rekruttering
- Taipei Veterans General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andre navne:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Eksperimentel: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Andre navne:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Aktiv komparator: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
Tidsramme: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Fase 2: Forekomst af anti-lægemiddel-antistof (ADA) mod PF-08634404
Tidsramme: Ca. 21 måneder
|
Ca. 21 måneder
|
|
|
Fase 3: Forekomst af ADA mod PF-08634404
Tidsramme: Cirka 21 måneder
|
Cirka 21 måneder
|
|
|
Fase 3: Ændring fra baseline i Functional Assessment of Cancer Therapy - Gastric (FACT-Ga) Total score
Tidsramme: Ca. 4 år
|
Ca. 4 år
|
|
|
Fase 3: Tid til definitiv forværring i FACT-Ga Total score
Tidsramme: Cirka 4 år
|
Cirka 4 år
|
|
|
Fase 3: Tid til definitiv forringelse i Gastric Cancer Subscale (GaCS)-score
Tidsramme: Cirka 4 år
|
Cirka 4 år
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
Tidsramme: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Tidsramme: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Tidsramme: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Tidsramme: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
Tidsramme: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
Tidsramme: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Pfizer CT.gov Call Center, Pfizer
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Neoplasmer i maven
- Adenocarcinom i spiserøret
- Aminosyrer, peptider og proteiner
- Proteiner
- Terapeutik
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Nivolumab
- Lægemiddelterapi
Andre undersøgelses-id-numre
- C6461016
- 2025-524717-86-00 (Registry Identifier: CTIS (EU))
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .